STERIS plc revised financial guidance for the fiscal year 2024. For fiscal 2024, the Company now expects as reported revenue to increase 10-11%, an increase from previous expectations of 9-10%. Expectations for constant currency organic revenue growth are also increased to 7-8% from prior expectations of 6-7%.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
204.1 USD | -0.24% | +1.01% | -6.82% |
Apr. 19 | Wolfe Research Adjusts STERIS Price Target to $235 From $245 | MT |
Apr. 11 | Sector Update: Health Care Stocks Steady Pre-Bell Thursday | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.82% | 20.21B | |
-3.46% | 184B | |
-2.43% | 107B | |
-3.91% | 67.78B | |
+1.49% | 50.66B | |
+10.46% | 47.64B | |
+4.60% | 41.12B | |
+1.62% | 26.3B | |
+1.25% | 26.04B | |
+15.06% | 25.4B |
- Stock Market
- Equities
- STE Stock
- News STERIS plc
- STERIS plc Revises Financial Guidance for the Fiscal Year 2024